Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
tirzepatide's 20.9% came at 72 weeks
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
Novo Nordisk remains confident in the benefit-risk profile of our GLP-1 medicines, when used consistent with their indications and product labeling. Eli Lilly sells the GIP and GLP-1 drug Tirzepatide, under the brand names of Mounjaro and Zepbound
WEGOVY increased from 989 users in 2021 to 2,992 in 2022, while MOUNJARO reached 1,508 users in 2022
Current evidence suggests that GLP-1 medications are safe for long-term use when monitored closely by a healthcare provider
TIRZEPATIDE: EFFICACY IN PHASE III CLINICAL TRIALS After the promising results in Phase I and Phase II trials, the SURPASS clinical trial programs were designed to assess the efficacy and safety of Tirzepatide as a treatment to improve glycaemic control in patients with T2D
US$ 29.92
US$ 28.00
US$ 24.09
US$ 22.18
